



57A-1623
#5
1-23-00

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.

BY: Carol S. Kaplan DATE: November 8, 1999

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of Brian J. Balin et al.	: Group Art Unit: 1623
		:
Appln. No.:	09/227,749	: Examiner: E. Peselev
		:
Filed:	January 8, 1999	:
		:
For:	TREATMENT AND DIAGNOSIS OF ALZHEIMER'S DISEASE	: Attorney Docket : No. 10062-1 (210062.0001)

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated October 8, 1999, Applicants hereby elect to prosecute the claims of Group I, claims 1-17, which are drawn to a method of treating either of Chlamydia pneumoniae infection and Alzheimer's disease, for prosecution on the merits in this application. This election is being made without traverse.

The Examiner has further subjected the claims of Group I to election of a single disclosed species of antibiotic recited in claims 1-17. The Examiner has identified the antibiotic species as being (a) a fluoroquinolone, (b) a sulfonamide, (c) a tetracycline, and (d) a macrolide. Applicants hereby elect for prosecution species (d), a macrolide antibiotic. Claims 1-17 read on a macrolide antibiotic. This election is being made without traverse.

Prompt consideration and allowance of claims 1-17 are respectfully requested.

Respectfully submitted,

Brian J. Balin et al.

November 8, 1999

(Date)

By: 

Kathryn Doyle, Ph.D., J.D.

Registration No. 36,317

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street - 22nd Floor

Philadelphia, PA 19103

Telephone: (215) 965-1200

Facsimile: (215) 965-1210

E-Mail: kdoyle@akingump.com

KD/csk